
Royal Jelly is a viscous substance secreted by worker bees and constitutes the essential food for queen bees and their larvae. It is consumed as a health food around the world. It demonstrated vasodilatory, hypotensive, antihypercholesterolemic, antitumor, anti-inflammatory effects and estrogenic activity (1) (3) (9) but its affinity for estrogen receptors is weaker compared to diethylstilbestrol and phytoestrogens (3). Royal Jelly was shown to stimulate MCF-7 cell proliferation which was reversed by tamoxifen (3). It also stimulated the production of collagen as well as other actions needed for bone formation via its action on osteoblasts (4). Royal Jelly may be effective against colitis (10). Oral administration of royal jelly improved testostrerone levels in male rabbits (19).
Clinical studies have demonstrated that Royal Jelly lowered total serum lipid levels and total serum cholesterol in individuals with moderately elevated cholesterol levels (5).
Mid-cycle peri-coital intravaginal applications of a combination of Egyptian bee honey and Royal Jelly improved infertility due to idiopathic asthenozoospermia (2). In an uncontrolled prospective observational study, Royal Jelly improved menopausal symptoms in postmenopausal women (6).
Because Royal Jelly has estrogenic effects, women with estrogen receptor-positive breast cancer should avoid this product; prostate cancer patients should also use caution as royal jelly increased testosterone levels in male rabbits.
Royal Jelly has demonstrated vasodilatory, hypotensive, antihypercholesterolemic and anti-inflammatory effects. It has also shown weak estrogenic activity (1). Four compounds have been identified in Royal Jelly that exhibit estrogenic activity; 1-hydroxy-trans-2-decenoic acid, 10-hydroxydecanoic acid, trans-2-decenoic acid and 24-methylenecholesterol. They inhibited the binding of estradiol to estrogen receptor beta but had little or no effects on binding to estrogen receptor alpha (4). Royal Jelly has been shown to inhibit the growth-promoting effects of the environmental estrogen bisphenol A on human breast cancer MCF-7 cells in-vitro (7). In-vitro studies also suggest that Royal Jelly stimulates the production of type 1 collagen as well as other actions needed for bone formation through its action on osteoblasts (4). The mechanism of action for the cholesterol-lowering effects of Royal Jelly is not yet known (5). It has previously been suggested that Royal Jelly decreases reabsorption of cholesterol in the GI tract and increases its excretion in the bile due to the presence of phytosterols, mainly B-sitosterol. Another explanation offered is that royal jelly suppresses hepatic cholesterol synthesis (8).
The pharmacokinetics of Royal jelly in humans have not been well documented.
Women with estrogen-receptor positive breast cancer should avoid products containing Royal Jelly as they may stimulate the cancer.
Guo H, Saiga A, Sato M, et al. Royal jelly supplementation improves lipoprotein metabolism in humans. J Nutr Sci Vitaminol (Tokyo). Aug 2007;53(4):345-348.
Fifteen healthy volunteers were randomized to receive 6 grams of Royal Jelly or to a control group for 4 weeks. Royal Jelly supplementation resulted in a 6% reduction in total cholesterol and a 9.1% reduction in LDL cholesterol. The levels of very-low-density-lipoprotein were also decreased. (p<0.05). There were no significant changes in HDL cholesterol or triglyceride levels. These results suggest that Royal Jelly may benefit individuals with high cholesterol levels.
Bottom Line: Royal Jelly may benefit those with high cholesterol. But it has not been shown to treat cancer in humans.
Royal Jelly is a viscous substance secreted by the worker bees and makes up the essential food for queen bees and their larvae. It is consumed as a health food around the world. Royal jelly has been shown to lower blood pressure; lower cholesterol levels; and reduce inflammation in laboratory and animal studies. It has not been studied as a cancer treatment in humans. Royal Jelly has weak estrogenic activity and should not be used by patients with hormone-sensitive cancer.